Authors	B. Urman, B. Ata, K. Yakin, C. Alatas, S. Aksoy, R. Mercan and B. Balaban
Journal	Human Reproduction
Year of publication	2009
Country	Turkey
Period	From January 2006 to May 2008.
Study Designer	Prospective randomized study
Randomization	Computer generated randomization prepared by one of the researchers. The study subjects were randomized in blocks of 10; that is, of every 10 randomized subjects, five were allocated to the LMWH arm and five were allocated to the control arm at random.
Inclusion criteria	-History of at least two transfer cycles of previously failed fresh embryos, as demonstrated with negative levels of human chorionic gonadotropin (hCG) in serum. -All previously failed cycles at the American Hospital in Istanbul. -Female age ≤38 years. -Fresh ejaculation sperm to be used for ICSI. No hormonal, clotting or immunological disorders have been detected. - Normal uterine cavity, assessed by hysteroscopy or serum-infused ultrasound. - Normal female and male peripheral karyotype
Exclusion criteria	Women requiring anticoagulant therapy for other medical reasons, obvious causes of implantation failure (transvaginal ultrasound visible hydrosalpinx, fibroids that distort the uterine cavity, absence of grade I, grade II embryos available for transfer or clinical or laboratory findings of congenital thrombophilia, or acquired.
Participant demographic data	Women aged between 29 and 41 years and with ≥2 failed assisted reproduction treatment cycles.
Types of interventions	Study group: LMWH (Enoxaparin Sodium, Clexane, Aventis Pharma) was administered at a dose of 1 mg/kg/day from the day after oocyte recovery. Control group: it received no medication other than progesterone gel.
Results measures	Primary result: continuous pregnancy rate. Secondary results: multiple pregnancy, implantation, continuous pregnancy at> 20 weeks, live births.
Results	The results of this pilot study suggest a potential beneficial effect of LMWH on the clinical outcome of assisted reproduction therapy (ART) in women with recurrent implantation failure (RIF). This finding, however, has yet to be corroborated by larger trials.